SCHEMBL320238

SCHEMBL320238

COC(=O)c1sc(-c2ccccc2)cc1N(CC(=O)N1CCOCC1)C(=O)[C@H]1CC[C@H](C)CC1

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CYP2E1 P05181 1/20 0.57
▸ KDM4E B2RXH2 2/20 0.45
▸ HTT P42858 1/20 0.45
▸ ATM Q13315 1/20 0.45
▸ HSD17B10 Q99714 1/20 0.40
▸ ABCC1 P33527 1/20 0.39
▸ MAPT P10636 5/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ GSTO1 P78417 1/20 0.38
▸ PTGS2 P35354 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ PDE4B Q07343 1/20 0.36
▸ TP53 P04637 1/20 0.35
▸ CHRM3 P20309 1/20 0.35
▸ NR1H4 Q96RI1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL320239 1.00 CYP2E1 (0.57) CYP2E1KDM4EHTTATMHSD17B10
SCHEMBL319087 0.94 CYP2E1 (0.54) CYP2E1KDM4EHTTATMHSD17B10
SCHEMBL319086 0.94 CYP2E1 (0.54) CYP2E1KDM4EHTTATMHSD17B10
SCHEMBL319050 0.91 CYP2E1 (0.67) CYP2E1HSD17B10ABCC1MAPTGSTO1
SCHEMBL319051 0.91 CYP2E1 (0.67) CYP2E1HSD17B10ABCC1MAPTGSTO1
SCHEMBL319108 0.87 CYP2E1 (0.61) CYP2E1KDM4EHTTHSD17B10ABCC1
SCHEMBL319107 0.87 CYP2E1 (0.61) CYP2E1KDM4EHTTHSD17B10ABCC1
SCHEMBL10265447 0.85 CYP2E1 (0.58) CYP2E1KDM4EALDH1A1
SCHEMBL10265449 0.85 CYP2E1 (0.61) CYP2E1MAPTALDH1A1
SCHEMBL15130860 0.85 CYP2E1 (0.58) CYP2E1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130190289-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-07-25 — — US disclosed
US-20130190289-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-07-25 — — US disclosed
US-20130190289-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-07-25 — — US disclosed
EP-2585447-A2 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS Vertex Pharmaceuticals Incorporated (US) 2013-05-01 — — EP disclosed
WO-2012006055-A2 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-01-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130190289-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS SLC10A1, ACE, CEL CYP2E1 1027/4885KDM4E 4146/4885HTT 1551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback